CIK 0001737953 · Non-accelerated filer<br>Smaller reporting company
Replimune Group, Inc.
Sign in to watch- Ticker
- REPL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 822082553
- Phone
- (781) 222-9600
- Business address
- 500 UNICORN PARK, WOBURN, MA, 01801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $654,036
- in 3 filings
Net −$654,036. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-01 | Weinand Dieter Director | Grant or award · Stock Option (right to buy) | +44,500 | 44,500 | ||
| 2026-02-18 | Astley-Sparke Philip Director | Gift | −25,000 | 1,380,071 | ||
| 2025-12-19 | Patel Sushil Chief Executive Officer | Grant or award | +200,000 | 533,576 | ||
| 2025-12-19 | Xynos Konstantinos Chief Medical Officer | Grant or award | +60,000 | 199,685 | ||
| 2025-12-19 | Hill Emily Luisa Chief Financial Officer | Grant or award | +60,000 | 194,368 | ||
| 2025-12-19 | Sarchi Christopher Chief Commercial Officer | Grant or award | +35,000 | 158,088 | ||
| 2025-12-19 | Schwendenman Andrew Chief Accounting Officer | Grant or award | +10,000 | 78,284 | ||
| 2025-12-09 | Dhingra Kapil Director | Option exercise | +3,169 | $1.75 | $6K | 3,169 |
| 2025-12-09 | Dhingra Kapil Director | Sale | −3,169 | $10.40 | $33K | 0 |
| 2025-12-09 | Dhingra Kapil Director | Option exercise · Stock Option (right to buy) | −3,169 | 0 | ||
| 2025-12-02 | Patel Sushil Chief Executive Officer | Sale 10b5-1 | −10,000 | $11.13 | $111K | 333,576 |
| 2025-11-17 | Sarchi Christopher Chief Commercial Officer | Sale | −5,208 | $9.10 | $47K | 123,088 |
| 2025-11-17 | Xynos Konstantinos Chief Medical Officer | Sale | −7,248 | $9.10 | $66K | 139,685 |
| 2025-08-15 | Hill Emily Luisa Chief Financial Officer | Sale | −9,154 | $5.37 | $49K | 134,368 |
| 2025-05-20 | Astley-Sparke Philip Director | Sale | −32,279 | $8.06 | $260K | 1,405,071 |
| 2025-05-20 | Xynos Konstantinos Chief Medical Officer | Sale | −7,952 | $8.06 | $64K | 146,933 |
| 2025-05-20 | Schwendenman Andrew Chief Accounting Officer | Sale | −3,287 | $8.05 | $26K | 68,284 |
| 2025-05-20 | Patel Sushil Chief Executive Officer | Sale | −25,105 | $8.06 | $202K | 343,576 |
| 2025-05-20 | Hill Emily Luisa Chief Financial Officer | Sale | −2,535 | $8.05 | $20K | 143,522 |
| 2025-05-20 | Sarchi Christopher Chief Commercial Officer | Sale | −3,749 | $8.05 | $30K | 128,296 |
Page 3 of 8 · 143 trades